#USA #New York #kidney function #creatinine #cystatin C

Disparities in Kidney Function Tests Indicate Serious Health Risks

A comprehensive study led by researchers from NYU Langone Health has revealed that discrepancies between two prevalent kidney function tests — creatinine and cystatin C — can serve as significant indicators of potential health complications, including kidney failure, heart disease, and even mortality. Monitoring kidney function is crucial, as it plays a vital role in determining appropriate medication dosages for various treatments. This groundbreaking research emphasizes the necessity of utilizing both tests to create a clearer picture of kidney health, particularly among older adults and those with existing health conditions.

Understanding Kidney Function Tests

For generations, healthcare providers have relied predominantly on creatinine levels to monitor kidney function. Creatinine is a waste product produced from muscle metabolism and is typically filtered out by healthy kidneys. Level assessments in the bloodstream indicate the efficiency of this filtration.

However, in recent years, increasing emphasis has been placed on another biomarker, cystatin C. Unlike creatinine, which can be influenced by factors such as muscle mass and diet, cystatin C is a protein released by all human cells, providing a potentially more accurate reflection of kidney filtration capabilities. Combining these two tests can offer deeper insights, potentially uncovering cases of reduced kidney function that may otherwise go unnoticed.

Key Findings from the Study

Conducted on a massive scale, involving 860,966 participants from diverse backgrounds, the study revealed that over one-third of hospitalized individuals exhibited significant discrepancies in their kidney test results. Specifically, those with cystatin C readings that were 30% lower than their creatinine measurements were identified as having a considerably heightened risk for severe health issues. Among these risks are elevated chances of heart diseases, kidney failure requiring dialysis, and even premature death.

Dr. Morgan Grams, a leading author of the study, pointed out that these findings underline the importance of assessing both biomarkers in understanding kidney health, particularly in patients who are older or suffering from other diseases. He remarked, "By detecting variations between these two tests, we can recognize kidney dysfunction earlier in its progression, ultimately enabling timely and effective interventions."

The Implications of Early Detection

The implications of this research extend beyond just understanding kidney health. With chronic kidney disease currently ranking as the ninth leading cause of death globally, identifying individuals at risk can lead to early treatment interventions, significantly improving outcomes and deferring the need for more invasive procedures like dialysis or transplants. This is particularly relevant in an era where the prevalence of chronic kidney issues continues to rise.

Additionally, the clinical applications of these findings are extensive. Assessing kidney function accurately is crucial not just for determining appropriate treatment plans for kidney disease, but also for ensuring that medications, such as chemotherapy drugs and antibiotics, are administered at safe levels. Misjudging a patient’s kidney function could lead to detrimental health consequences.

The Need for Comprehensive Testing

Despite the substantial benefits of conducting both tests, it’s concerning that a mere fraction of clinical laboratories in the United States currently perform cystatin C tests. A 2019 survey reported that fewer than 10% of labs had implemented in-house cystatin C testing, underscoring a significant gap in standard kidney health assessments in many healthcare providers and hospitals.

Dr. Josef Coresh, another co-author of the study, accentuates the need for increased adoption of cystatin C testing, especially as its availability grows. He cautioned that physicians might overlook vital information regarding their patients' health, while also emphasizing the importance for patients to advocate for comprehensive evaluations based on these guidelines.

Conclusion

This pioneering research not only sheds light on the critical role of kidney function tests but also opens the door for further exploration into better diagnosing and treating chronic kidney disease. By enhancing the way kidney health is monitored, the medical community can strive towards reducing risks associated with kidney dysfunction and improving patient outcomes globally.

Published in the Journal of the American Medical Association and presented at the American Society of Nephrology's annual conference, these findings lay the groundwork for enhanced clinical practices regarding kidney health assessments. As awareness grows and testing methodologies evolve, swift and effective action can be taken to tackle chronic kidney issues head-on, ultimately saving lives.